Our findings show an association between use of semaglutide for type 2 diabetes and risk of NAION, the researchers concluded
To view a copy of this licence, visit About this article Cite this article Kucuk, T., Horozal, P.E., Karakulak, A
While the exact mechanisms through which semaglutide exerts its cardiovascular benefits are not fully understood, several theories have been proposed: The positive impact of semaglutide on cardiovascular outcomes has created a new paradigm in treating type 2 diabetes, where the cardiovascular benefit is now a key consideration in selecting an antidiabetic therapy
For food and beverage manufacturers, GLP-1 drugs are unlikely to eliminate demand for indulgent products
Peeters B, Benninga MA, Hennekam RC (2011)
You feel full sooner, you eat less, and yes, you drop some pounds